|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis显示文摘AIM: To determine the clinical impact of portal vein thrombosis in terms of both mortality and hepatic decompensations(variceal hemorrhage, ascites, portosystemic encephalopathy) in adult patients with cirrhosis.METHODS: We identified original articles reported through February 2015 in MEDLINE, Scopus, Science Citation Index, AMED, the Cochrane Library, and relevant examples available in the grey literature. Two independent reviewers screened all citations for inclusion criteria and extracted summary data. Random effects odds ratios were calculated to obtain aggregate estimates of effect size across included studies, with 95%CI.RESULTS: A total of 226 citations were identified and reviewed, and 3 studies with 2436 participants were included in the meta-analysis of summary effect. Patients with portal vein thrombosis had an increased risk of mortality(OR = 1.62, 95%CI: 1.11-2.36, P = 0.01). Portal vein thrombosis was associated with an increased risk of ascites(OR = 2.52, 95%CI: 1.63-3.89, P < 0.001). There was insufficient data available to determine the pooled effect on other markers of decompensation including gastroesophageal variceal bleeding or hepatic encephalopathy. CONCLUSION: Portal vein thrombosis appears to increase mortality and ascites, however, the relatively small number of included studies limits more generalizable conclusions. More trials with a direct comparison group are needed. | Jonathan G Stine Puja M Shah Scott L Cornella Sean R Rudnick Marwan S Ghabril George J Stukenborg Patrick G Northup | 2015 | World Journal of Hepatology2015，7，27： | 42 |
| 2 | Metastatic gastric cancer treatment: Second line and beyond显示文摘Advanced gastric cancer(a GC), not amenable to curative surgery, is still a burdensome illness tormenting afflicted patients and their healthcare providers. Whereas combination chemotherapy has been shown to improve survival and tumor related symptoms in the frontline setting, second-line therapy(SLT) is subject to much debate in the scientific community, mainly because of the debilitating effects of GC, which would impede the administration of cytotoxic therapy. Recent data has provided sufficient evidence for the safe use of SLT in patients with an adequate performance status. Taxanes, Irinotecan and even some Fluoropyrimidine analogs were found to provide a survival advantage in this subset of patients. Most importantly, quality of life measures were also improved through the use of adequate therapy. Even more pertinent were the findings involving antiangiogenic agents, which would add measurable improvements without significantly jeopardizing the patients' well-being. Further lines of therapy are cause for much more debate nowadays, but specific targeted agents have shown considerable promise in this context. We herein review noteworthy published data involving the use of additional lines of the therapy after failure of standard frontline therapies in patients with a GC. | Marwan Ghosn Samer Tabchi Hampig Raphael Kourie Mustapha Tehfe | 2016 | World Journal of Gastroenterology2016，22，11： | 10 |
| 3 | Cooperative deterministic learning control for a group of homogeneous nonlinear uncertain robot manipulators显示文摘This paper addresses the learning control problem for a group of robot manipulators with homogeneous nonlinear uncertain dynamics, where all the robots have an identical system structure but the reference signals to be tracked differ. The control objective is twofold: to track on reference trajectories and to learn/identify uncertain dynamics. For this purpose, deterministic learning theory is combined with consensus theory to find a common neural network(NN) approximation of the nonlinear uncertain dynamics for a multi-robot system. Specifically, we first present a control scheme called cooperative deterministic learning using adaptive NNs to enable the robotic agents to track their respective reference trajectories on one hand and to exchange their estimated NN weights online through networked communication on the other. As a result, a consensus about one common NN approximation for the nonlinear uncertain dynamics is achieved for all the agents. Thus, the trained distributed NNs have a better generalization capability than those obtained by existing techniques. By virtue of the convergence of partial NN weights to their ideal values under the proposed scheme, the cooperatively learned knowledge can be stored/represented by NNs with constant/converged weights, so that it can be used to improve the tracking control performance without re-adaptation. Numerical simulations of a team of two-degree-of-freedom robot manipulators were conducted to demonstrate the effectiveness of the proposed approach. | Marwan ABDELATTI Chengzhi YUAN Wei ZENG Cong WANG | 2018 | Science China(Information Sciences)2018，61，11： | 7 |
| 4 | Optimum chemotherapy in the management of metastatic pancreatic cancer显示文摘Pancreatic cancer is one of the most devastating solid tumors,and it remains one of the most difficult to treat.The treatment of metastatic pancreatic cancer(MPC)is systemic,based on chemotherapy or best supportive care,depending on the performance status of the patient.Two chemotherapeutical regimens have produced substantial benefits in the treatment of MPC:gemcitabine in 1997;and FOLFIRIONOX in 2011.FOLFIRINOX improved the natural history of MPC,with overall survival(OS)of 11.1 mo.Nab-paclitaxel associated with gemcitabine is a newly approved regimen for MPC,with a median OS of 8.6 mo.Despite multiple trials,this targeted therapy was not efficient in the treatment of MPC.Many new molecules targeting the proliferation and survival pathways,immune response,oncofetal signaling and the epigenetic changes are currently undergoing phaseⅠandⅡtrials for the treatment of MPC,with many promising results. | Marwan Ghosn Hampig Raphael Kourie Fadi El Karak Colette Hanna Joelle Antoun Dolly Nasr | 2014 | World Journal of Gastroenterology2014，20，9： | 7 |
| 5 | Incidence, risk factors and outcomes of de novo malignancies post liver transplantation显示文摘Liver transplantation(LT) is associated with a 2 to7 fold higher, age and gender adjusted, risk of de novo malignancy. The overall incidence of de novo malignancy post LT ranges from 2.2% to 26%, and 5 and 10 years incidence rates are estimated at 10% to 14.6% and 20% to 32%, respectively. The main risk factors for de novo malignancy include immunosuppression with impaired immunosurveillance, and a number of patient factors which include; age, latent oncogenic viral infections, tobacco and alcohol use history, and underlying liver disease. The most common cancers after LT are non-melanoma skin cancers, accounting for approximately 37% of de novo malignancies, with a noted increase in the ratio of squamous to basal cell cancers. While these types of skin cancer do not impact patient survival, post-transplant lymphoproliferative disorders and solid organ cancer, accounting for 25% and 48% of malignancies, are associated with increased mortality. Patients developing these types of cancer are diagnosed at more advanced stages, and their cancers behave more aggressively compared with the general population. Patients undergoing LT for primary sclerosing cholangitis(particularly with inflammatory bowel disease) and alcoholic liver disease have high rates of malignancies compared with patients undergoing LT for other indications. These populations are at particular risk for gastrointestinal and aerodigestive cancers respectively. Counseling smoking cessation, skin protection from sun exposure and routine clinical follow-up are the current approach in practice. There are no standardized surveillance protocol, but available data suggests that regimented surveillance strategies are needed and capable of yielding cancer diagnosis at earlier stages with better resulting survival. Evidence-based strategies are needed to guide optimal surveillance and safe minimization of immunosuppression. | Pavan Kedar Mukthinuthalapati Raghavender Gotur Marwan GhabrilMarwan Ghabril | 2016 | World Journal of Hepatology2016，8，12： | 7 |
| 6 | Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis显示文摘BACKGROUND The coexistence of sarcopenia and obesity is referred to as sarcopenic obesity(SO)and it has been hypothesized that the two components of SO may synergistically increase their negative effects. However, many uncertainties still surround this condition especially with regard to its potential negative effects on health outcomes.AIM To conduct a systematic review to determine the prevalence of sarcopenia among adults with overweight and obesity and to investigate whether SO was associated with a higher risk of type 2 diabetes(T2 D).METHODS This study was conducted in adherence with the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. Literature searches, study selection, methodology development and quality appraisal were performed independently by two authors and the data were collated by means of metaanalysis and narrative synthesis.RESULTS Of the 606 articles retrieved, 11 studies that comprised a total of 60118 adults with overweight and obesity of both genders met the inclusion criteria and were reviewed, revealing two main findings. First, the overall prevalence of sarcopenia is 43% in females and 42% in males who are with overweight and obesity.Secondly, the presence of SO increases the risk of T2D by 38% with respect to those without SO(OR = 1.38, 95%CI: 1.27-1.50).CONCLUSION A high prevalence of sarcopenia has been found among adults with overweight and obesity regardless of their gender and this condition seems to be associatedwith a higher risk of T2D. Clinician should be aware of this scenario in their clinical practice for the better management of both obesity and T2D. | Dima Khadra Leila Itani Hana Tannir Dima Kreidieh Dana El Masri Marwan El Ghoch | 2019 | World Journal of Diabetes2019，10，5： | 6 |
| 7 | 长江流域侵蚀产沙尺度效应的区域分异显示文摘以长江流域水文站点的观测数据为依据,基于一定的分区原则,将整个长江流域分成了8个区域,对所有分区产沙模数的尺度效应进行了深入分析。研究表明,所有分区产沙模数的尺度效应可以概括为三类:产沙模数随流域面积的增大而减小,或先减小后基本保持不变的,主要包括长江中下游干流沿岸区域,岷江主体区域,洞庭湖流域和鄱阳湖流域;产沙模数随流域面积的增大基本保持不变的,包括嘉陵江主体区域和汉江流域;产沙模数随流域面积增大而增大,或先增大后基本保持不变的,包括长江上游干流沿岸的非泥石流区域和乌江流域。不同流域尺度效应的差异主要与流域土地利用方式有关。基于各分区校正方程,将所有站点进行了标准面积为100 km2,1 000 km2,10 000 km2的尺度校正,结果表明,当校正面积为100 km2,侵蚀最强烈的区域主要是岷江流域,其次是鄱阳湖和洞庭湖流域,校正面积为1 000 km2和10 000 km2,产沙模数图变化不显著,但明显区别于校正面积为100km2下的产沙模数图。侵蚀最强烈的区域主要是嘉陵江流域,其次是长江上游干流沿岸的部分区域和汉江流域的部分区域。不同校正面积下产沙模数图的变化,显示了不同流域侵蚀来源的差异。 | 闫云霞 许炯心 Marwan Hasson 廖建华 | 2011 | 山地学报2011，29，2： | 5 |
| 8 | Cinnamaldehyde protects against rat intestinal ischemia/reperfusion injuries by synergistic inhibition of NF-κB and p53显示文摘Our preliminary study shows that cinnamaldehyde(CA)could protect against intestinal ischemia/reperfusion(I/R)injuries,in which p53 and NF-κB p65 play a synergistic role.In this study,we conducted in vivo and in vitro experiments to verify this proposal.SD rats were pretreated with CA(10 or 40 mg·kg−1·d−1,ig)for 3 days,then subjected to 1 h mesenteric ischemia followed by 2 h reperfusion.CA pretreatment dose-dependently ameliorated morphological damage and reduced inflammation evidenced by decreased TNF-α,IL-1β,and IL-6 levels and MPO activity in I/R-treated intestinal tissues.CA pretreatment also attenuated oxidative stress through restoring SOD,GSH,LDH,and MDA levels in I/R-treated intestinal tissues.Furthermore,CA pretreatment significantly reduced the expression of inflammation/apoptosis-related NF-κB p65,IKKβ,IK-α,and NF-κB p50,and downregulated apoptotic protein expression including p53,Bax,caspase-9 and caspase-3,and restoring Bcl-2,in I/R-treated intestinal tissues.We pretreated IEC-6 cells in vitro with CA for 24 h,followed by 4 h hypoxia and 3 h reoxygenation(H/R)incubation.Pretreatment with CA(3.125,6.25,and 12.5μmol·L−1)significantly reversed H/R-induced reduction of IEC-6 cell viability.CA pretreatment significantly suppressed oxidative stress,NF-κB activation and apoptosis in H/R-treated IEC-6 cells.Moreover,CA pretreatment significantly reversed mitochondrial dysfunction in H/R-treated IEC-6 cells.CA pretreatment inhibited the nuclear translocation of p53 and NF-κB p65 in H/R-treated IEC-6 cells.Double knockdown or overexpression of p53 and NF-κB p65 caused a synergistic reduction or elevation of p53 compared with knockdown or overexpression of p53 or NF-κB p65 alone.In H/R-treated IEC-6 cells with double knockdown or overexpression of NF-κB p65 and p53,CA pretreatment caused neither further decrease nor increase of NF-κB p65 or p53 expression,suggesting that CA-induced synergistic inhibition on both NF-κB and p53 played a key role in ameliorating intestinal I/R injuries.Finally,we used immunoprecipitation assay to demonstrate an interaction between p53 and NF-κB p65,showing the basis for CA-induced synergistic inhibition.Our results provide valuable information for further studies. | Marwan Almoiliqy Jin Wen Bin Xu Yu-chao Sun Meng-qiao Lian Yan-li Li Eskandar Qaed Mahmoud Al-Azab Da-peng Chen Abdullah Shopit Li Wang Peng-yuan Sun Yuan Lin | 2020 | Acta Pharmacologica Sinica2020，41，9： | 5 |
| 9 | Anal cancer treatment:Current status and future perspectives显示文摘Anal cancers(AC)are relatively rare tumors.Their incidence is increasing,particularly among men who have sex with other men due to widespread infection by human papilloma virus.The majority of anal cancers are squamous cell carcinomas,and they are treated according to stage.In local and locally advanced AC,concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil(5-FU)is the current best treatment,while metastatic AC,chemotherapy with 5-FU and cisplatin remains the gold standard.There are no indications for induction or maintenance therapies in locally advanced tumors.Many novel strategies,such as targeted therapies,vaccination,immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC,with promising results in some indications. | Marwan Ghosn Hampig Raphael Kourie Pamela Abdayem Joelle Antoun Dolly Nasr | 2015 | World Journal of Gastroenterology2015，21，8： | 4 |
| 10 | 非线性时间序列的复杂网络分析显示文摘近十多年,运用复杂网络的方法进行时间序列分析,是非线性动力学发展的最新方向,为传统的以混沌理论为基础的非线性时间序列分析注入了新生力量,在刻画动力系统非线性特征方面,提供了很多崭新的见解,在很多不同领域内都取得了广泛应用.本文回顾三种主要的方法:递归网络、可视图以及转换网络.着重介绍三种网络方法的理论基础和各自的最新进展.本文将指明今后时间序列网络方法的发展方向,并为实际数据分析提供指导作用. | 邹勇 DONNER Reik V MARWAN Norbert DONGES Jonathan F KURTHS Jürgen | 2020 | 中国科学:物理学、力学、天文学2020，50，1： | 3 |
| 11 | Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases显示文摘AIM: To investigate the impact of RAS and BRAF mutations on the pattern of metastatic disease and carcinoembryonic antigen(CEA) production.METHODS: In this retrospective study, we investigated the impact of RAS and BRAF mutational status on pattern of metastatic disease and CEA production. Only patients presenting with a newly diagnosed metastatic colorectal cancer(CRC) were included. Patients' characteristics, primary tumor location, site of metastatic disease and CEA at presentation were compared between those with and without RAS and BRAF mutations.RESULTS: Among 174 patients, mutations in KRAS, NRAS and BRAF were detected in 47%, 3% and 6% respectively. RAS mutations(KRAS and NRAS) were more likely to be found in African American patients(87% vs 13%; P value = 0.0158). RAS mutations were associated with a higher likelihood of a normal CEA(< 5 ng/mL) at presentation. BRAF mutations were more likely to occur in females. We were not able to confirm any association between mutational status and site of metastatic disease at initial diagnosis.CONCLUSION: No association was found between RAS and BRAF mutations and sites of metastatic disease at the time of initial diagnosis in our cohort. Patients with RAS mutations were more likely to present with CEA levels < 5 ng/mL. These findings may have clinical implications on surveillance strategies for RAS mutant patients with earlier stages of CRC. | may cho chie akiba cecilia lau david smith milhan telatar michelle afkhami stephen sentovich kurt melstrom marwan fakih | 2016 | World Journal of Gastrointestinal Oncology2016，8，1： | 3 |
| 12 | 患者对书面知情同意的理解:问卷研究显示文摘目的检验患者对手术知情同意书的地位、作用、以及免除知情同意的理解。设计前瞻性问卷调查研究。问卷于术后一个月发给患者。答卷按频数和单变量分析。地点大型教学医院。参加者 732名已在妇产科接受手术超过6个月的患者。主要结果评价患者对知情同意书法律含义的认识,以及患者关于知情同意书的作用和免除书面知情同意的观点。结果患者对知情同意书法律地位的理解非常有限。将近一半的患者(46%,95%可信区间43%~50%)认为同意书的基本作用是保护医院,68%(65%~71%)的人认为同意书让医生行使控制权。只有41%(37%~44%)的患者认为同意书使医生了解患者的愿望。结论许多患者对他们签署或者不签署同意书的法律含义知之有限,他们也没有认识到同意书的基本作用是保护他们自己的利益。看来目前作为一种表达自主选择的方法,同意程序还不够充分,而且其伦理地位及可信区间令人质疑。 | Andrea Akkad Clare Jackson Sara Kenyon Mary Dixon-Woods Nick Taub Marwan Habiba 翟小梅(译) | 2007 | 英国医学杂志中文版2007，10，2： | 3 |
| 13 | M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals显示文摘BACKGROUND Assessing liver fibrosis is important for predicting the efficacy of direct-acting antivirals(DAAs)and patient prognosis.Non-invasive techniques to assess liver fibrosis are becoming important.Recently,serum Mac-2 binding protein glycosylation isomer(M2BPGi)was identified as a non-invasive marker of liver fibrosis.AIM To investigate the diagnostic accuracy of M2BPGi in assessing liver fibrosis in patients with chronic hepatitis C(CHC)treated with DAAs.METHODS From December 2017 to August 2018,80 treatment-naive adult patients with CHC who were eligible for DAAs therapy were consecutively enrolled in this observational cohort study.For 12 weeks,65 patients were treated with sofosbuvir/daclatasvir,and 15 patients were treated with sofosbuvir/daclatasvir and a weight-based dose of ribavirin at knowledge and technology association for hepatitis C management clinic,Cairo,Egypt.We measured serum M2BPGi levels,PAPAS index,fibrosis-4(FIB-4)score and liver stiffness measurements(LSM)at baseline and 12 weeks after the end of treatment.Serum M2BPGi levels were measured using enzyme-linked immunosorbent assay.RESULTS All patients achieved sustained virologic response(SVR12)(100%).Serum M2BPGi levels,LSM,FIB-4 score and PAPAS index decreased significantly at SVR12(P<0.05).Serum M2BPGi levels correlated positively with LSM at baseline and SVR12(P<0.001).At baseline,compared with the FIB-4 score and PAPAS index,M2BPGi was the best marker to distinguish patients with grade F4 fibrosis(AUC=0.801,P<0.001),patients with grade F2 from grade F0-1 fibrosis(AUC=0.713,P=0.012),patients with grade F3-4 from grade F0-2 fibrosis(AUC=0.730,P<0.001),and patients with grade F2-4 from grade F0-1 fibrosis(AUC=0.763,P<0.001).At SVR12,M2BPGi had the greatest AUCs for differentiating patients with grade F4 fibrosis(AUC=0.844,P<0.001),patients with grade F3 from grade F0-2 fibrosis(AUC=0.893,P=0.002),patients with grade F3-4 from grade F0-2 fibrosis(AUC=0.891,P<0.001),and patients with grade F2-4 from grade F0-1 fibrosis(AUC=0.750,P<0.001).CONCLUSION M2BPGi is a reliable marker for the non-invasive assessment and prediction of liver fibrosis regression in patients with CHC who achieved an SVR with DAAs therapy. | Shereen A Saleh Mohamed M Salama Marwan M Alhusseini Ghada A Mohamed | 2020 | World Journal of Gastroenterology2020，26，21： | 3 |
| 14 | Optimum chemotherapy for the management of advanced biliary tract cancer显示文摘Biliary tract cancers(BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis.The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status.Despite clinical trials studyingmany chemotherapeutic regimens and targeted therapies for the treatment of BTC, the standard of care for advanced BTC remains the combination of gemcitabine with cisplatin.Many new molecules targeting proliferation and survival pathways, the immune response and angiogenesis are currently undergoing phase Ⅰ and Ⅱ trials for the treatment of advanced BTC with promising results. | Marwan Ghosn Hampig Raphael Kourie Elie El Rassy Ralph Chebib Fadi El Karak Colette Hanna Dolly Nasr | 2015 | World Journal of Gastroenterology2015，21，14： | 2 |
| 15 | Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature显示文摘Ampullary carcinoma(AC) is a rare gastrointestinal tumor without clear treatment recommendations.The management of this tumor is usually extrapolated from the treatment of pancreatic,biliary duct and intestinal cancers.Few papers have studied the AC as an independent entity and yet succombs to several limitations.These studies were retrospective single institutional experiences with limited sample sizes recruited over a long period of time.Unlike metastatic ACs where chemotherapy is the only recommended option,localized AC once excised may be approached by either chemotherapy alone or concomitant chemoradiation therapy.In this review,we report the overall survival and recurrence factors of more than 1000 patients from all the studies treating exclusively ACs.We also review the medical treatment of this tumor and conclude to the necessity of multi-institutional randomized controlled studies for AC exclusively. | Marwan Ghosn Hampig Raphael Kourie Elie El Rassy Fady Ghassan Haddad Colette Hanna Fadi El Karak Dolly Nasr | 2016 | World Journal of Gastrointestinal Oncology2016，8，10： | 2 |
| 16 | Dilemma of first line regimens in metastatic pancreatic adenocarcinoma显示文摘Pancreatic cancer is one of the deadliest cancers,ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer(m PC) remains cytotoxic chemotherapy. In 2016, more than 40 years after the introduction of gemcitabine in the management of m PC, the best choice for first-line treatment has not yet been fully elucidated. Two main strategies have been adopted to enhance treatment efficacy. The first strategy is based on combining non-cross resistant drugs, while the second option includes the development of newer generations of chemotherapy. More recently, two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel(GNP), have both been shown to improve overall survival in comparison with gemcitabine alone, at the cost of increased toxicity. Therefore, the best choice for first line therapy is a matter of debate. For some authors, FOLFIRINOX should be the first choice in patients with an Eastern Cooperative Oncology Group score(0-1) given its lower hazard ratio. However, others do not share this opinion. In this paper, we review the main comparison points between FOLFIRINOX and GNP. We analyze the two pivotal trials to determine the similarities and differences in study design. In addition, we compare the toxicity profile of the two regimens as well as the impact on quality of life. Finally, we present studies revealing real life experiences and review the advantages and disadvantages of possible second-line therapies including their cost effectiveness. | Marwan Ghosn Tony Ibrahim Tarek Assi Elie El Rassy Hampig Raphael Kourie Joseph Kattan | 2016 | World Journal of Gastroenterology2016，22，46： | 2 |
| 17 | High-pitch spiral acquisition: A new scan mode for coronary CT angiography显示文摘 | Stephan Achenbach Mohamed Marwan Tiziano Schepis Tobias Pflederer Herbert Bruder Thomas Allmendinger Martin Petersilka Katharina Anders Michael Lell Axel Kuettner Dieter Ropers Werner G. Daniel Thomas Flohr | 2009 | Journal of Cardiovascular Computed Tomography2009，，2： | 2 |
| 18 | Cephalometric evaluation of craniofacial pattern of syrian children with class III malocclusion显示文摘 | Marwan Mouakeh | 2001 | American Journal of Orthodontics & Dentofacial Orthopedics2001，，6： | 2 |
| 19 | Prospectively ECG-triggered high-pitch spiral acquisition for coronary CT angiography using dual source CT: technique and initial experience显示文摘 | Michael Lell Mohamed Marwan Tiziano Schepis Tobias Pflederer Katharina Anders Thomas Flohr Thomas Allmendinger Willi Kalender Dirk Ertel Carsten Thierfelder Axel Kuettner Dieter Ropers Werner G. Daniel Stephan Achenbach | 2009 | European Radiology2009，，11： | 2 |
| 20 | The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding显示文摘 | Brian H. Hyett Marwan S. Abougergi Joseph P. Charpentier Navin L. Kumar Suzana Brozovic Brian L. Claggett Anne C. Travis John R. Saltzman | 2012 | Gastrointestinal Endoscopy2012，，： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员